Figures obtained under an FOI request show the NHS spent a whopping £250million in the past five years on treatment for trans ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...

New study highlights the potential benefits of breast ultrasound as a supplemental screening tool for women with dense breast ...

Award-winning research presented at ESR 2025 reveals energy-efficient diagnostic approaches for metastatic breast cancer, ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...

The home expert has grown close to fans' hearts. Here she shares about the habits and daily pill that help her stay strong.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4 ...

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...